SEATTLE, April 19, 2022–(BUSINESS WIRE)–AVM Biotechnology, a clinical-stage company developing AVM0703, a small molecule that mobilizes the endogenous gamma delta TCR+ and invariant TCR+ Natural Killer Bispecific T-Type Cells, today announced that Founder and Chief Scientific Officer, Dr. Theresa Deisher, will give a guest company presentation as well as a poster presentation at Life Science Innovation Northwest taking place May 20 and April 21 at the Washington State Convention Center in Seattle. The oral presentation will feature a discussion of AVM0703, the company’s lead asset, as well as a clinical update on the status of the WWRD: AVM0703 study for the treatment of lymphoma and leukemia. (NCT04329728). Dr. Deisher’s presentation is scheduled for Wednesday, April 20and at 11:20 a.m. in the oncology and immunology session.

This press release is multimedia. See the full version here:

(Graphic: Business Wire)

AVM0703 is a small molecule that triggers the production and release of endogenous bispecific gamma delta TCR+ and invariant TCR+ T-type natural killer cells (AVM-NKT). These natural enhanced immune cells have unique properties and appear rapidly in the blood after a single dose of AVM0703 which can be administered at an infusion center. Preclinical data suggests even greater efficacy in combination with chemotherapy as well as potential in solid tumors and autoimmune diseases. AVM0703 offers advantages over existing standard oncology treatments because AVM-NKT cells are induced in vivo and do not face the same manufacturing and supply challenges as other cell therapies.

Dr. Deisher will provide a clinical update on the near completion of the safety portion of the company’s pivotal clinical trial in the treatment of patients with “no option” non-Hodgkin’s lymphoma/relapsed/refractory leukemia, as well as surprising results in a patient enrolled in the FDA-cleared Expanded Access or Compassionate Use Program. The drug was generally well tolerated in patients with mild to moderate, self-limiting side effects.

AVM Biotechnology’s mission is to develop and deliver treatments that save lives and improve outcomes by unlocking the potential of the body’s immune system. The company has raised nearly $25 million to date, including approximately 20% in non-dilutive funding. They recently received a $1.6 million SBIR Phase II grant from the National Institute of Diabetes and Digestive Kidney Diseases to study the reversal and prevention of type 1 diabetes and a letter of intent for funding. from the National Cancer Institute for an additional $2 million Phase II. SBIR grant to continue existing clinical trial. AVM will seek breakthrough therapy designation, expedited FDA review, and accelerated approval in non-Hodgkin’s lymphoma (NHL) while simultaneously exploring the potential of AVM0703 in type 1 diabetes. Commercialization in NHL is planned for the first quarter of 2024.

Life Science Innovation Northwest, the largest annual life science conference in the Pacific Northwest, brings together investors, public and private life science organizations, research institutions, scientists, entrepreneurs and the global health community to discuss and showcase some of the most compelling recent lives. scientific breakthroughs. Dr. Deisher is delighted to highlight AVM Biotechnology’s transformative work in this context. To register, go to Northwest Life Sciences Innovation 2022 | Washington Life Sciences.

For more information about AVM Biotechnology, contact Jena Dalpez at [email protected] or 206-906-9922 or via

Forward-looking statement

This contains certain statements which constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements do not relate strictly to historical or current facts and may be accompanied by words such as “may” , “would”, “could”, “potentially”, “suggest”, “believe”, “expect”, “should” and other similar words or expressions. These forward-looking statements reflect our current beliefs as of the date of publication. and are subject to risks, uncertainties, assumptions, changed circumstances and other factors; the development and commercialization of drugs is highly risky and early clinical results in animals or humans may not reflect full results of later-stage or larger-scale clinical trials. These forward-looking statements are subject to risks and uncertainties that could cause our actual results, performance and expectations to differ materially from those expressed or implied by such statements, including statements regarding: future and ongoing drug development and timing; applications of drugs to specific diseases; the potential for results from ongoing preclinical or clinical trials; FDA or other regulatory findings and approvals; potential market opportunities; and the occurrence of future events or circumstances. There are risks and uncertainties involving, but not limited to, our ability to progress our research and development efforts, conduct clinical trials, achieve expected results, commercialize our products, avoid infringement of rights patients, trademarks and other proprietary rights of third parties, to protect products from competition, to navigate the political environment, to maintain sufficient capital and funding, to avoid problems with our manufacturing processes, to maintain our operations and to obtain regulatory approval to sell and market the drugs in the United States and elsewhere. The reader should not place undue reliance on these forward-looking statements. We are under no obligation to publicly release the results of any revisions to any of our forward-looking statements to reflect events or circumstances after the date such statements are made or to reflect the occurrence of unforeseen events, unless the law requires it.

See the source version on


AVM Biotechnology
Jena Dalpez
[email protected]